{"entity":{"id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Ribociclib, Fulvestrant in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.","summary":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06726148 by Novartis Pharmaceuticals, with 280 participants planned, started 2025-04-03 and due to reach its primary completion in 2028-09-25. Interventions recorded: ECI830, ribociclib, fulvestrant. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06726148","url":"https://clinicaltrials.gov/study/NCT06726148"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["cdk46-inhibitor"],"targets":[],"drugs":["ribociclib","fulvestrant"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06726148","phase":"1/2","setting":"An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT06726148","source":"https://clinicaltrials.gov/study/NCT06726148","fetchedAt":"2026-10-07T16:54:58.037Z","studySha256":"8d7bfb64d3f5be02dd4bac3c606cebe64fef97a418b02cfc9a54a8ad238c04e5","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-27","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"100 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":280,"enrolmentType":"ESTIMATED","siteCount":33,"recruitingSiteCount":33,"countries":["Australia","Canada","China","Czechia","Denmark","France","Germany","Israel","Italy","Japan","Singapore","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2025-04-03","startedType":"actual","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06726148/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}